Unibest
← Back to patent-cliff list

BH015

Tier C — Watch / trade

BH015

-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type

Targets:Updating

Indications (approved):Bladder cancer

Regional status

US
-
EU
-
China
Phase II
2026-07-21
Japan
-

Synthetic routes & intermediates

Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.

Frequently asked questions

What are the approved indications of BH015?

Approved indications include: Bladder cancer.

When does the BH015 patent expire?

No public expiry year is available for BH015 yet; this page updates once verified.

How do I get a quote for BH015 intermediates?

Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.

Source: cross-verified data (structured fields only) · 2026-09-29